Unifiram (DM-232) is an ampakine-like drug derived from biarylpropylsulfonamide, and has antiamnesic and other effects in animal studies with up to a thousand times higher potency than piracetam. A number of related compounds are known, including sunifiram (DM-235).
Unifiram has two enantiomers, with (R)-(+)-unifiram (dextrounifiram) being the more active isomer. Unifiram is shown to reduce the duration of hypnosis without impairing motor coordination.
The entry of unifiram into the nootropic scene caught the attention of the entire community of nootropic users, as initial studies suggest that it is estimated to be approximately 1,000 times more potent than piracetam. Unifiram is categorized as an ampakine due to its mode of action to affect its nootropic properties.
Ampakines interact strongly with the brain’s glutameric AMPA receptor, an action believed to enhance one’s cognitive processes such as memory retention and recall, learning abilities, logical reasoning, mental focus, and verbal fluency. Unifiram, along with other ampakines, are currently being studied for its potential to cure a number of conditions related to mental disability including Alzheimer’s Diseases, Attention Deficit Hyperactivity Disorder (ADHD), Parkinson’s Disease, and treatment resistant depression (TRD).